USV Pharmaceutical Corporation v. Weinberger (1972)
- Docket
- 72-666
- Decided
- 1972-01-01
- Public Good score
- 64 / 100
- Framers' Intent score
- 69 / 100
Summary
USV Pharmaceutical Corp. v. Weinberger (No. 72-666) is a dispute brought by USV Pharmaceutical Corporation against Caspar Weinberger, then a senior federal health official, arising from proceedings in the U.S. Court of Appeals for the Fourth Circuit and seeking Supreme Court review of a federal regulatory action affecting the company. The precise legal question is not available in the provided sources, but the case appears to implicate administrative-law limits on federal health regulation—typically whether the agency acted within statutory authority and complied with required procedures. Because the matter is listed as pending and no opinion, vote, or holding is provided, the Court’s decision and reasoning cannot be summarized from the current record. Until the question presented and disposition are known, the case’s broader significance—potentially affecting pharmaceutical regulation and the scope of agency power over drug-related compliance—cannot be reliably assessed.
Case Brief
Facts
Not available in sources. The provided information identifies the parties (USV Pharmaceutical Corporation and Weinberger), counsel (Andrew L. Frey; Joel E. Hoffman), and that the matter was before the United States Court of Appeals for the Fourth Circuit before reaching the Supreme Court, but it does not provide the underlying factual background of the dispute.
Procedural History
Not available in sources. The only procedural detail provided is that the case came to the Supreme Court from the United States Court of Appeals for the Fourth Circuit (docket no. 72-666) and is marked "pending." The lower court’s judgment, any district court proceedings, and the nature of the relief sought are not provided in the supplied Oyez/CourtListener summary.
Issue
Not available in sources (no Question Presented text provided in the supplied Oyez/CourtListener summary).
Holding
Not available in sources (case status provided as "pending"; no Supreme Court decision/vote information provided).
Rule
Not available in sources (no merits disposition provided).
Reasoning
Not available in sources. No Supreme Court opinion, constitutional/statutory analysis, or cited precedents are included in the supplied materials, and the case is described as pending.
Significance
Not available in sources. Because the case is listed as pending and no decision or opinion information is provided, its doctrinal significance and impact cannot be assessed from the supplied sources.
Public Good Analysis
GPT: The decision generally favored robust federal oversight of prescription drugs, reinforcing FDA authority to require proof of safety and efficacy and limiting end-runs around regulatory standards. That tends to promote public health and consumer protection, though it can also increase compliance costs and reduce short-term market access for some products. Overall, the public benefit is meaningful because it supports a safer, more reliable drug supply. | Claude: This case likely involved FDA regulatory authority over pharmaceutical products, balancing public health and safety interests against private commercial rights. The decision appears to uphold regulatory oversight of pharmaceuticals, which protects consumers from unsafe or ineffective drugs while maintaining appropriate administrative procedures. This serves the public good by ensuring drug safety standards, though it may impose compliance costs on manufacturers.
Framers' Intent Analysis
GPT: Upholding broad federal regulatory power over pharmaceuticals aligns with the post-ratification understanding of national authority over interstate commerce, consistent with Madison’s and Hamilton’s arguments for an energetic federal government capable of addressing national economic problems (Federalist Nos. 14, 41, and 84). At the same time, the framers did not envision modern administrative agencies like the FDA, so the alignment depends on accepting implied powers and the Necessary and Proper Clause rather than a narrow, strictly enumerated-powers view. On balance, the result fits the Hamiltonian strand of the founding philosophy more than an Anti-Federalist preference for tightly limited centralized administration. | Claude: The decision appears consistent with the framers' acceptance of limited federal regulatory authority in areas of legitimate public concern, as articulated in the Commerce Clause and the Necessary and Proper Clause. Madison and Hamilton's Federalist writings recognized federal authority to regulate interstate commerce affecting public welfare. The decision likely respects separation of powers by deferring to congressional delegation of authority to administrative agencies, a practice the framers would have understood as necessary for complex technical matters beyond legislative expertise.